(redirected from Dermatop)


any of the hormones produced by the adrenal cortex; also, their synthetic equivalents. Called also adrenocortical hormone and adrenocorticoid. All the hormones are steroids having similar chemical structures, but quite different physiologic effects. Generally they are divided into glucocorticoids (cortisol, cortisone, and corticosterone), mineralocorticoids (aldosterone and desoxycorticosterone, and also corticosterone) and androgens.

Patients who must take exogenous adrenal corticosteroids to supplement a deficit in endogenous cortisol or as a treatment for metastatic breast cancer should be thoroughly instructed in self-medication. Their needs are somewhat similar to those of the insulin-dependent diabetic patient. They should know the prescribed dosage and basic therapeutic action of the oral corticosteroid preparation they are taking and should be aware of the importance of taking the medication at the same time every day. The medication should never be discontinued abruptly for any reason. It is advisable that the patient carry an extra prescription when traveling, in case the supply is used up before returning home. These patients also need to wear some form of medical identification so that all health care professionals with whom they come in contact will know that they are receiving hormones of this kind. This includes dentists, oral surgeons, emergency department personnel, and others who might not be familiar with the patient's medical history.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.
References in periodicals archive ?
Dermatop Emollient Cream (prednicarbate emollient cream 0.1%, Dermik Laboratories)
Dermatop (prednicarbate) Emollient Cream 0.1% for treatment of mild to moderate eczema.
The others are Eulexin, Nimotop, Relafen, Dermatop, Penetrex, and Cardiogen-82.
The drugs covered by the bills, besides Claritin, are: Daypro (from Searle for arthritis), Dermatop (from Ortho Dermatological Inc.
The other potential candidates for patent extensions are ScheringPlough's cancer drug Eulexin; Bayer Corp.'s calcium channel blocker Nimotop; SmithKline Beecham PLC's nonsteroidal anti-inflammatory medication (NSAID) Relafen; Dermatop, Ortho Dermatological's corticosteroid emollient cream; RhonePouleneu Rorer Pharmaceuticals Inc.'s antibacterial drug Penetrex; Braccol Diagnostics' diagnostic agent Cardiogen-82; and G.D.
Drugs that would have realized major financial gains from the amendment were Claritin and Eulex-in, both made by Schering-Plough Corp.; SmithKline Beecham PLC'S Relafen; Cardiogen 82, made by Bristol-Myers Squibb Co.; Dermatop. from Hoechst Marion Roussel Inc.; Penetrex, of Rhone-Poulenc Rorer Inc.; and Nimotop, made by Bayer AG.